| scholarly article | Q13442814 |
| P2093 | author name string | E I Peerschke | |
| C A Sullivan | |||
| B S Coller | |||
| L E Scudder | |||
| P2860 | cites work | gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors | Q24301146 |
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Continuous cultures of fused cells secreting antibody of predefined specificity | Q26776979 | ||
| A Film Detection Method for Tritium-Labelled Proteins and Nucleic Acids in Polyacrylamide Gels | Q29547782 | ||
| Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes | Q33339989 | ||
| Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII | Q33462122 | ||
| Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis | Q33463842 | ||
| An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's Thrombasthenia | Q33463846 | ||
| Thromboxane Synthesis and the Platelet Release Reaction in Bernard-Soulier Syndrome, Thrombasthenia Glanzmann and Hermansky-Pudlak Syndrome | Q33471694 | ||
| Exposure of platelet fibrinogen receptors by ADP and epinephrine | Q33473239 | ||
| Cycles of Agglutination-Disagglutination Induced by Ristocetin in Thrombasthenic Platelets | Q33473264 | ||
| Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann's thrombasthenia type I and type II. | Q33478516 | ||
| Antibodies against platelet membrane glycoproteins. II. Influence on ADP- and collagen-induced platelet aggregation, crossed immunoelectrophoresis studies and relevance to Glanzmann's thrombasthenia | Q33478542 | ||
| Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients | Q33483874 | ||
| A molecular defect in thrombasthenic platelets | Q35194630 | ||
| New Data on Glanzmann's Thrombasthenia | Q36562989 | ||
| A role for prostaglandins and thromboxanes in the exposure of platelet fibrinogen receptors | Q37004238 | ||
| Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen | Q37007168 | ||
| Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome | Q37021542 | ||
| Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody | Q37026661 | ||
| Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody | Q37609861 | ||
| The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH | Q39088121 | ||
| Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose | Q39218339 | ||
| Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A | Q39513417 | ||
| ??? | Q64800736 | ||
| Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens | Q39548957 | ||
| A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines | Q39683818 | ||
| Plasmin inhibition of thrombin-induced platelet aggregation | Q39735110 | ||
| Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis | Q40261271 | ||
| Interrelations of Platelet Aggregation and Secretion | Q40691389 | ||
| Ionophore a 23187 and thrombasthenic platelets : a model for dissociating serotonin release and thromboxane formation from true aggregation | Q41139007 | ||
| Human platelets possess an inducible and saturable receptor specific for fibrinogen | Q41629256 | ||
| Studies on the factor VIII/von Willebrand factor antigen on human platelets | Q45878348 | ||
| The effect of stir bar size and shape on quantitative platelet aggregation | Q47342077 | ||
| Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia | Q47818855 | ||
| Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. | Q52433899 | ||
| Inhibition of von Willebrand factor-dependent platelet function by increased platelet cyclic AMP and its prevention by cytoskeleton-disrupting agents | Q52499595 | ||
| Numbers of Receptor Sites from Scatchard Graphs: Facts and Fantasies | Q52715482 | ||
| Effects of Adenosine Diphosphate and Adrenaline on Mean Platelet Shape | Q52760646 | ||
| Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin | Q66955875 | ||
| The effects of citrate and extracellular calcium ions on the platelet release reaction induced by adenosine diphosphate and collagen | Q66968585 | ||
| Human Normal and Leukemia Cell Surface Antigens. Mouse Monoclonal Antibodies as Probes | Q67016230 | ||
| Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function | Q67325000 | ||
| Effects of ADP and ATP on Bovine Fibrinogen- and Ristocetin-Induced Platelet Aggregation in Glanzmann's Thrombasthenia | Q67348850 | ||
| Asialofibrinogen supports platelet aggregation and adhesion to glass | Q67466902 | ||
| Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis | Q67556563 | ||
| Clot retraction: evaluation in dilute suspensions of platelet-rich plasma and gel-separated platelets | Q67740203 | ||
| The Effect of Platelet Membrane Antibodies on Aggregation and Release | Q68935471 | ||
| Platelet Shape Change and Aggregation | Q69379124 | ||
| Isolation, purification, and partial characterization of platelet membrane glycoproteins IIb and IIIa | Q70539259 | ||
| The formation of Ca++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis | Q70549345 | ||
| Glycoproteins of platelet membranes from Glanzmann's thrombasthenia. A comparison with normal using carbohydrate-specific or protein-specific labelling techniques and high-resolution two-dimensional gel electrophoresis | Q70664632 | ||
| Platelet membrane studies in the May-Hegglin anomaly | Q70820919 | ||
| Platelet Adhesion Induced by Fibrinogen Adsorbed onto Glass | Q71115194 | ||
| Ristocetin--a new tool in the investigation of platelet aggregation | Q71153335 | ||
| Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia | Q71493148 | ||
| Correlation between fibrinogen binding to human platelets and platelet aggregability | Q71496685 | ||
| Crossed immunoelectrophoresis of human platelet membranes. The major antigen consists of a complex of glycoproteins, GPIIb and GPIIIa, held together by Ca2+ and missing in Glanzmann's thrombasthenia | Q71606383 | ||
| Fibrinogen and platelets in the primary arrest of bleeding. Studies in two patients with congenital afibrinogenemia | Q71787277 | ||
| Influence of fibrinogen on the aggregation of washed human blood platelets induced by adenosine diphosphate, thrombin, collagen, and adrenaline | Q72645911 | ||
| Platelet function in congenital afibrinogenemia | Q72654398 | ||
| Involvement of divalent cations in the complex between the platelet glycoproteins IIb and IIIa | Q72656125 | ||
| Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex | Q72771425 | ||
| Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies | Q72779664 | ||
| Platelet function in a patient with thrombasthenia | Q72811872 | ||
| Aggregation, adhesion, and viscous metamorphosis of platelets in congenital fibrinogen deficiencies | Q72868848 | ||
| Effects of chymotrypsin and adenosine diphosphate on the exposure of fibrinogen receptors on normal human and Glanzmann's thrombasthenic platelets | Q72895038 | ||
| EFFECT OF FIBRINOGEN ON THE AGGREGATION OF PLATELETS BY ADENOSINE DIPHOSPHATE | Q77201766 | ||
| PLASMA THROMBOCYTE-AGGLUTINATING ACTIVITY AND FIBRINOGEN. SYNERGISM WITH ADENOSINE DIPHOSPHATE | Q78308703 | ||
| The preparation of human fibrinogen free of plasminogen | Q79027094 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 325-338 | |
| P577 | publication date | 1983-07-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa | |
| P478 | volume | 72 |
| Q42914519 | A High-Throughput Biotin-Avidin-ELISA for Studying Expression of Platelet Membrane Glycoproteins and Its Clinical Application |
| Q33426970 | A monoclonal antibody against rat platelets. I. Tissue distribution in vitro and in vivo |
| Q55488560 | A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIb-IIIa complex |
| Q34536168 | A monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells |
| Q34518712 | A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder |
| Q34541247 | A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex |
| Q77631587 | A new short chain RGD-containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation |
| Q41159249 | A novel activating anti-beta1 integrin monoclonal antibody binds to the cysteine-rich repeats in the beta1 chain |
| Q30433609 | A novel ultrasound-based method to evaluate hemostatic function of whole blood |
| Q34565483 | A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane |
| Q82022655 | Abciximab for thrombolysis during intracranial aneurysm coiling |
| Q37176419 | Abciximab: a review and update for clinicians |
| Q36233288 | Activated platelets form protected zones of adhesion on fibrinogen and fibronectin-coated surfaces |
| Q43889368 | Activation of recombinant alphaIIbbeta3 expressed in Chinese hamster ovary cells exposes different binding sites for fibrinogen or von Willebrand factor: evidence using monoclonal antibodies to alphaIIbbeta3. |
| Q34125159 | Adenosine diphosphate-induced aggregation of human platelets in flow through tubes. II. Effect of shear rate, donor sex, and ADP concentration |
| Q30310976 | Adhesion efficiency, platelet density and size |
| Q37711758 | Adhesive interactions of platelets and their blockade |
| Q52524567 | Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. |
| Q35395426 | Altered expression of the platelet aggregation-associated protein from Streptococcus sanguis after growth in the presence of collagen |
| Q37929839 | Anti-platelet therapy: glycoprotein IIb-IIIa antagonists |
| Q44772211 | Antibody-detectable changes in fibrinogen adsorption affecting platelet activation on polymer surfaces |
| Q33453656 | Antigenic differences between human platelets and megakaryocytes |
| Q28194430 | Antiplatelet drugs |
| Q35752619 | Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q43573530 | Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting |
| Q45937919 | Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. |
| Q36407213 | Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. |
| Q33869597 | Applications of anti-platelet monitoring in catheterization laboratory |
| Q34521638 | Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation |
| Q33477082 | Association of fibrin with the platelet cytoskeleton |
| Q40919205 | Binding of fibrinogen to human monocytes |
| Q47776894 | Biochemical and functional characterization of a new murine monoclonal antibody against human platelet glycoprotein IIIa |
| Q35593515 | Biogenesis of the platelet receptor for fibrinogen: evidence for separate precursors for glycoproteins IIb and IIIa |
| Q37513170 | Biography of Barry S. Coller |
| Q24563415 | Blasts from the past |
| Q40430655 | Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy |
| Q33495303 | Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function |
| Q73854553 | Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2 |
| Q74551385 | Blood flow and antithrombotic drug effects |
| Q35798423 | Bound fibrinogen distribution on stimulated platelets. Examination by confocal scanning laser microscopy |
| Q67538652 | Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation |
| Q36742054 | Calcium indirectly regulates immunochemical reactivity and functional activities of the N-domain of thrombospondin-1. |
| Q71673136 | Chemokines of the alpha, beta-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 |
| Q30573816 | Chemoproteomic discovery of AADACL1 as a regulator of human platelet activation. |
| Q46004699 | Chimeric fibrolase: covalent attachment of an RGD-like peptide to create a potentially more effective thrombolytic agent. |
| Q61669026 | Clinical experience with antithrombotic drugs acting on purine receptor pathways |
| Q33500262 | Clinical pharmacology of eptifibatide |
| Q27663824 | Closed headpiece of integrin IIb 3 and its complex with an IIb 3-specific antagonist that does not induce opening |
| Q37623550 | Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. |
| Q33735575 | Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. |
| Q34500263 | Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs. |
| Q70215753 | Comparison of platelet fibrinogen receptors on intact and proteolytically-treated platelets by use of an antiglycoprotein IIIa monoclonal antibody (MA 123) |
| Q42834201 | Conformation-dependent platelet adhesion to collagen involving integrin alpha 2 beta 1-mediated and other mechanisms: multiple alpha 2 beta 1-recognition sites in collagen type I. |
| Q51751592 | Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex. |
| Q41758589 | Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression |
| Q47142348 | Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets |
| Q36407225 | Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis |
| Q42097831 | Crotalus atrox venom preconditioning increases plasma fibrinogen and reduces perioperative hemorrhage in a rat model of surgical brain injury. |
| Q38675637 | Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism |
| Q35925710 | Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit |
| Q36947785 | Distinct role of Pyk2 in mediating thromboxane generation downstream of both G12/13 and integrin αIIbβ3 in platelets |
| Q56945080 | Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc |
| Q57591186 | Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia |
| Q28165946 | Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting |
| Q33885186 | Effects of limiting extension at the alphaIIb genu on ligand binding to integrin alphaIIbbeta3. |
| Q35585012 | Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon |
| Q33331867 | Efficacy of abciximab readministration in coronary intervention. |
| Q39689511 | Equine hemostasis. Description, evaluation, and alteration |
| Q42796528 | Evidence for novel binding sites on the platelet glycoprotein IIb and IIIa subunits and immobilized fibrinogen |
| Q36233149 | Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa |
| Q70201984 | Evidence that three adhesive proteins interact with a common recognition site on activated platelets |
| Q73487466 | Expression and function of calcium binding domain chimeras of the integrins alpha(IIb) and alpha(5) |
| Q40865226 | Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin |
| Q43510108 | Fibrin clot retraction by human platelets correlates with alpha(IIb)beta(3) integrin-dependent protein tyrosine dephosphorylation |
| Q33476961 | Fibrinogen interaction with platelet receptors |
| Q37397492 | Fibrinogen mitogenic effect on hemopoietic cell lines: control via receptor modulation |
| Q67952462 | Flow cytometric analysis of platelet surface antigens |
| Q93081135 | From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent |
| Q37215081 | Functional and computational studies of the ligand-associated metal binding site of beta3 integrins |
| Q34528200 | Functionally thrombasthenic state in normal platelets following the administration of ticlopidine |
| Q41737288 | Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition |
| Q38155124 | Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention |
| Q34119585 | Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb. |
| Q37360713 | Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection |
| Q35008537 | Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment |
| Q35583999 | Glycoprotein IIb/IIIa Receptor Inhibitors in Acute ST-Elevation Myocardial Infarction: Will the Combination with Thrombolytics Become Reality? |
| Q33337743 | Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes |
| Q42139077 | Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond. |
| Q33742233 | Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging |
| Q36220256 | High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets |
| Q35185593 | Historical perspective and future directions in platelet research |
| Q39641908 | Human fibrinogen |
| Q34520405 | Identification of the thrombin receptor on human platelets by chemical crosslinking |
| Q41125713 | Immunocytochemical aspects of platelet membrane glycoproteins and adhesive proteins during activation. |
| Q39820977 | Immunodiagnosis and immunotherapy of childhood malignancies |
| Q37946818 | Immunoscintigraphy of thrombosis |
| Q74172108 | Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease |
| Q34565552 | Independent modulation of von Willebrand factor and fibrinogen binding to the platelet membrane glycoprotein IIb/IIIa complex as demonstrated by monoclonal antibody |
| Q37393216 | Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets |
| Q74187728 | Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes |
| Q37358508 | Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". |
| Q37011736 | Integrin αIIbβ3: from discovery to efficacious therapeutic target |
| Q36288115 | Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. |
| Q34624945 | Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation |
| Q41403458 | Interrelation of platelet aggregation, release reaction and thromboxane A2 production |
| Q34549309 | Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation |
| Q67531969 | Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? |
| Q24314835 | Isolation of the thrombospondin membrane receptor |
| Q39396524 | Kindlin-3 mediates integrin αLβ2 outside-in signaling, and it interacts with scaffold protein receptor for activated-C kinase 1 (RACK1). |
| Q30984034 | Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion |
| Q28156404 | Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity |
| Q35804502 | Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation |
| Q38573695 | Mechanism of platelet aggregation induced by a monoclonal antibody requiring Fc portion |
| Q40571401 | Mechanistic insights from a refined three-dimensional model of integrin alphaIIbbeta3. |
| Q56944438 | Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions |
| Q28190575 | Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy |
| Q38737720 | Molecular cloning, expression and assembly of multimeric von Willebrand factor |
| Q34147628 | Monitoring antiplatelet therapy: What is the best method? |
| Q73848594 | Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography |
| Q37711747 | Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents |
| Q35812008 | Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs |
| Q36806108 | Mutation of a conserved asparagine in the I-like domain promotes constitutively active integrins alphaLbeta2 and alphaIIbbeta3. |
| Q40608458 | Mutations in and near the second calcium-binding domain of integrin alphaIIb affect the structure and function of integrin alphaIIbbeta3. |
| Q51471544 | Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph. |
| Q41711755 | New antiplatelet drugs |
| Q40727618 | New antithrombotic strategies for resistant thrombotic processes |
| Q44408524 | Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets |
| Q37943829 | Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions |
| Q33768927 | Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction |
| Q36179701 | Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary |
| Q40559317 | Pharmacology of current and future antithrombotic therapies. |
| Q36914754 | Phorbol ester induces c-sis gene transcription in stem cell line K-562. |
| Q36994814 | Plasminogen interacts with human platelets through two distinct mechanisms |
| Q64970706 | Platelet Contributions to Myocardial Ischemia/Reperfusion Injury. |
| Q38547727 | Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future |
| Q41091401 | Platelet Imaging in Man using Antiplatelet Monoclonal Antibodies |
| Q41914250 | Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity |
| Q33951293 | Platelet adhesion receptors: novel targets for anti-thrombotic therapy |
| Q34673739 | Platelet adhesion under flow |
| Q74551383 | Platelet aggregation in flow: differential roles for adhesive receptors and ligands |
| Q34282877 | Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors |
| Q28192464 | Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? |
| Q40582616 | Platelet factors predisposing to arterial thrombosis |
| Q33334039 | Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes |
| Q34180960 | Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction |
| Q35680598 | Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review |
| Q33336362 | Platelet glycoprotein IIb/IIIa receptor antagonists |
| Q31934867 | Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease |
| Q33914229 | Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients |
| Q36019811 | Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection |
| Q36368770 | Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18) |
| Q24650652 | Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses |
| Q90206995 | Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets |
| Q47720581 | Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. |
| Q69875023 | Prenatal diagnosis of Glanzmann's thrombasthenia |
| Q33931454 | Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features |
| Q33835575 | Protein 4.1R-deficient mice are viable but have erythroid membrane skeleton abnormalities |
| Q28288816 | Purification and partial characterization of CD9 antigen of human platelets |
| Q37849171 | Radiopharmaceuticals for thrombus detection |
| Q43188550 | Rationally designed integrin beta3 mutants stabilized in the high affinity conformation |
| Q40829771 | Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. |
| Q36211385 | Redistribution of the fibrinogen receptor of human platelets after surface activation |
| Q74387689 | Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery |
| Q42483407 | Regulation of ligand binding to glycoprotein IIb-IIIa (integrin αIIbβ3) in isolated platelet membranes |
| Q41295506 | Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1. |
| Q36007725 | Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling |
| Q33449399 | Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo |
| Q34619920 | Role of thrombospondin in platelet aggregation |
| Q28166387 | Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis |
| Q33470320 | Separation of important new platelet glycoproteins (GPIa, GPIc, GPIc*, GPIIa and GMP-140) by f.p.l.c. Characterization by monoclonal antibodies and gas-phase sequencing |
| Q41954139 | Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s) |
| Q35213036 | Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics |
| Q33909935 | Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen |
| Q27301036 | Swing-out of the β3 hybrid domain is required for αIIbβ3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen |
| Q36080411 | The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells |
| Q33381441 | The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend |
| Q47776991 | The Membrane Glycoprotein IIb/IIIa Complex Mediates Deposition of Thrombin-stimulated Blood Platelets on Polystyrene Plastic Under Static Conditions |
| Q41138768 | The amino acid sequence Gly-Ala-Pro-Leu appears to be a fibrinogen binding site in the platelet integrin, glycoprotein IIb |
| Q41773241 | The design and testing of a dual fiber textile matrix for accelerating surface hemostasis |
| Q39560070 | The diagnosis of acute deep venous thrombosis: noninvasive and radioisotopic techniques |
| Q33477774 | The expression of glycoproteins on single blood platelets from healthy individuals and from patients with congenital bleeding disorders |
| Q73025870 | The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies |
| Q33875329 | The importance of N-glycosylation on β3 integrin ligand binding and conformational regulation |
| Q34175105 | The platelet: life on the razor's edge between hemorrhage and thrombosis |
| Q33367036 | The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes |
| Q35080401 | The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention |
| Q36224126 | The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin |
| Q27680395 | Three-dimensional reconstruction of intact human integrin IIb 3: new implications for activation-dependent ligand binding |
| Q40486965 | Thrombin and antithrombotic therapy in interventional cardiology |
| Q34177216 | Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo |
| Q35597837 | Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions |
| Q38222143 | Thrombolysis. An approach still on the move |
| Q40433424 | Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives |
| Q33569283 | Thrombosis and antithrombotic therapy in women |
| Q37688909 | Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody |
| Q51553879 | Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. |
| Q36357988 | Translating from the rivers of Babylon to the coronary bloodstream |
| Q37215078 | Translational research: forging a new cultural identity |
| Q33846628 | Tyrosine-specific protein phosphorylation is regulated by glycoprotein IIb-IIIa in platelets |
| Q38118745 | Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice |
| Q41525205 | Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes |
| Q40347050 | Vitronectin binds to activated human platelets and plays a role in platelet aggregation |
| Q33444536 | Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor |
| Q73538114 | [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes] |
| Q40348390 | alphaIIbbeta3 biogenesis is controlled by engagement of alphaIIb in the calnexin cycle via the N15-linked glycan |
| Q70321843 | von Willebrand disease |
| Q34208569 | von Willebrand factor binding to platelet GpIb initiates signals for platelet activation |
| Q34574601 | von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia |
| Q89777927 | αIIbβ3 binding to a fibrinogen fragment lacking the γ-chain dodecapeptide is activation dependent and EDTA inducible |
Search more.